uniQure N.V. Payments to Acquire Held-to-maturity Securities
uniQure N.V. (QURE) reported Payments to Acquire Held-to-maturity Securities of $658.38 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireHeldToMaturitySecurities · last filed 2026-05-05
- uniQure N.V. payments to acquire held-to-maturity securities for the quarter ending 2025-12-31 was $441.25M, a 449.81% increase year-over-year.
- uniQure N.V. payments to acquire held-to-maturity securities for the quarter ending 2025-09-30 was $96.92M, a 23.47% decline year-over-year.
- uniQure N.V. payments to acquire held-to-maturity securities for the quarter ending 2025-06-30 was $55.43M, a 19.85% decline year-over-year.
- uniQure N.V. payments to acquire held-to-maturity securities for the quarter ending 2025-03-31 was $64.78M, a 22.68% decline year-over-year.
- uniQure N.V. payments to acquire held-to-maturity securities for fiscal 2025 was $658.38M, a 82.96% increase from fiscal 2024.
- uniQure N.V. payments to acquire held-to-maturity securities for fiscal 2024 was $359.84M, a 1.80% decline from fiscal 2023.
- uniQure N.V. payments to acquire held-to-maturity securities for fiscal 2023 was $366.44M, a 124.61% increase from fiscal 2022.
- uniQure N.V. payments to acquire held-to-maturity securities for fiscal 2022 was $163.15M.
| Period end | Payments to Acquire Held-to-maturity Securities 3 month | Payments to Acquire Held-to-maturity Securities 6 month | Payments to Acquire Held-to-maturity Securities 9 month | Payments to Acquire Held-to-maturity Securities 12 month |
|---|---|---|---|---|
| 2025-12-31 | $441.25M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $538.17M derived: sum of 2 quarters · filed 2026-03-02 | $593.60M derived: sum of 3 quarters · filed 2026-03-02 | $658.38M 10-K · filed 2026-03-02 |
| 2025-09-30 | $96.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $152.35M derived: sum of 2 quarters · filed 2025-11-10 | $217.12M 10-Q · filed 2025-11-10 | $297.38M derived: sum of 4 quarters · filed 2026-05-05 |
| 2025-06-30 | $55.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-29 | $120.20M 10-Q · filed 2025-07-29 | $200.46M derived: sum of 3 quarters · filed 2026-05-05 | $327.11M derived: sum of 4 quarters · filed 2026-05-05 |
| 2025-03-31 | $64.78M 10-Q · filed 2026-05-05 | $145.03M derived: sum of 2 quarters · filed 2026-05-05 | $271.68M derived: sum of 3 quarters · filed 2026-05-05 | $340.84M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $80.25M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $206.91M derived: sum of 2 quarters · filed 2026-03-02 | $276.06M derived: sum of 3 quarters · filed 2026-03-02 | $359.84M 10-K · filed 2026-03-02 |
| 2024-09-30 | $126.65M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $195.81M derived: sum of 2 quarters · filed 2025-11-10 | $279.59M 10-Q · filed 2025-11-10 | $279.59M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | $69.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-29 | $152.94M 10-Q · filed 2025-07-29 | $152.94M derived: sum of 3 quarters · filed 2026-03-02 | |
| 2024-03-31 | $83.78M 10-Q · filed 2025-05-09 | $83.78M derived: sum of 2 quarters · filed 2026-03-02 | ||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $366.44M 10-K · filed 2026-03-02 | ||
| 2023-09-30 | $366.44M 10-Q · filed 2024-11-05 | |||
| 2022-12-31 | $163.15M 10-K · filed 2025-02-27 | |||
| 2021-12-31 | $0.00 10-K · filed 2023-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |